A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.
Researchers at the University of Texas Health Science Center at San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation.
